Business
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., November 13, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update.
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/d026b37e33ade289b4e5de6a72530f32"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hZY.MrWXycCTrrnTy6bn3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d026b37e33ade289b4e5de6a72530f32","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5t.294Dt_ay4B0odVP52bw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d026b37e33ade289b4e5de6a72530f32","width":1200,"height":325}},"lazy":false},{"type":"text","content":"PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Complete; Topline results expected by calendar year end","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., November 13, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update.","length":418,"tagName":"p"},{"type":"text","content":""As we conclude the second quarter of our fiscal year, we are encouraged by our progress and remain confident in the path ahead," said Shawn Singh, President and Chief Executive Officer of Vistagen. "We are on track to report topline data from the randomized portion of our PALISADE-3 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder this quarter, followed by the randomized portion of our PALISADE-4 Phase 3 trial in 2026. We have built strong momentum toward the primary goal of our PALISADE program, developing what we hope could be the first FDA-approved acute treatment of social anxiety disorder for the 30 million adults living with this serious and potentially life-threatening condition."","length":747,"tagName":"p"},{"type":"text","content":"Program Highlights","length":18,"tagName":"p"},{"type":"text","content":"Fasedienol for the Acute Treatmen...